finance.yahoo.com

Novartis Pelacarsen Fails to Cut Cardiovascular Events in Phase 3

Novartis logoNovartis
Sig2.60Sen-1.90Env0.00Soc-0.80Gov0.00
Ionis Pharmaceuticals logoIonis Pharmaceuticals
Sig1.35Sen-1.05Env0.00Soc0.00Gov0.00

Pelacarsen lowered lipoprotein(a) in Novartis’ Phase 3 Lp(a)HORIZON study but did not achieve a statistically significant reduction in cardiovascular events. BofA called the outcome disappointing yet contained, keeping a Buy rating and $185 target while investors focus on four other Phase 3 readouts expected in 2H 2026. Novartis reported 39 Phase 3 projects and three programs in registration.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro